Loading...
•
Mar 31, 2023
Pulse Biosciences Q1 2023 Earnings Report
Pulse Biosciences reported financial results for Q1 2023 and provided business updates.
Key Takeaways
Pulse Biosciences reported a GAAP net loss of $9.8 million for the first quarter of 2023, compared to a $17.3 million loss in the prior year period. Cash and cash equivalents totaled $54.1 million as of March 31, 2023. The company advanced its preclinical and regulatory objectives for its two novel nsPFA devices.
Advanced preclinical and regulatory objectives for surgical ablation clamp and cardiac ablation catheter.
Preclinical evidence continues to demonstrate differentiated benefits of nsPFA.
Expanded leadership team with the appointment of Chief Medical Officer, Dr. Gan Dunnington.
Total GAAP cost and expenses were $9.6 million, compared to $17.7 million for the prior year period.
Forward Guidance
Pulse Biosciences is focused on the development of its nsPFA technology for use in electrophysiology and the treatment of atrial fibrillation.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...